Alendronate-Grafted Nanoemulsions for Bone-Targeted Vincristine Delivery: Preliminary Studies on Cell and Animal Models.

alendronate nanoemulsion vincristine

Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
18 Feb 2024
Historique:
received: 02 01 2024
revised: 13 02 2024
accepted: 16 02 2024
medline: 24 2 2024
pubmed: 24 2 2024
entrez: 24 2 2024
Statut: epublish

Résumé

Bone is a site of distant metastases, which are a common cause of morbidity and mortality with a high socio-economic impact, for many malignant tumours. In order to engineer pharmacological therapies that are suitable for this debilitating disease, this experimental work presents injectable lipid nanoemulsions, which are endowed with a long history of safe clinical usage in parenteral nutrition, their loading with vincristine and their grafting with alendronate, with a dual purpose: merging the anticancer activity of bisphosphonates and vincristine, and enhancing bone-targeted delivery. In cell studies, alendronate synergised with the anti-migration activity of vincristine, which is important as migration plays a key role in the metastatisation process. In preliminary animal studies, carried out thanks to IVIS technology, alendronate conjugation enhanced the bone targeting of fluorescently labelled nanoemulsions. These encouraging results will drive further studies on suitable animal models of the disease.

Identifiants

pubmed: 38397475
pii: biom14020238
doi: 10.3390/biom14020238
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Italian Association for Cancer Research
ID : IG20714
Organisme : Compagnia di San Paolo
ID : Bando ex post 2020
Organisme : Fondazione CRT
ID : 2021.1856
Organisme : University of Turin
ID : Ricerca Locale 2019-2022

Auteurs

Ian Stoppa (I)

Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont (UPO), via Solaroli 17, 28100 Novara, Italy.

Chiara Dianzani (C)

Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.

Nausicaa Clemente (N)

Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont (UPO), via Solaroli 17, 28100 Novara, Italy.

Annalisa Bozza (A)

Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.

Valentina Bordano (V)

Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.

Sara Garelli (S)

Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.

Luigi Cangemi (L)

Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.

Umberto Dianzani (U)

Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont (UPO), via Solaroli 17, 28100 Novara, Italy.

Luigi Battaglia (L)

Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.
Nanostructured Interfaces and Surfaces (NIS) Interdepartmental Centre, University of Turin, 10124 Turin, Italy.

Classifications MeSH